Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer

ÇAKIR, Erol; ERBAŞ, Hakan; BAL, Oğuz

Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer

Hakan ERBAŞ, (Trakya Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Edirne, Türkiye)

Oğuz BAL, (Trakya Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Edirne, Türkiye)

Erol ÇAKIR (Trakya Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Edirne, Türkiye)

Balkan Medical Journal

1 0

Yıl: 2015 Cilt: 32 Sayı: 1 Sayfa Aralığı: 89 - 95 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer

Öz:

Background: Breast cancer is the most common malignant tumour of women around the world. As a key enzyme of the urea cycle, arginase leads to the formation of urea and ornithine from L-arginine. In the patients with several different cancers, arginase has been found to be higher and reported to be a useful biological marker. Aims: The aim of this study was to investigate the effect of rosuvastatin on serum and cancer tissue arginase enzyme activity, and ornithine and polyamine (putrescine, spermidine, spermine) levels. Study Design: Animal experiment. Methods: In this study, 50 male Balb/c mice were used. Erchlich acid tumour cells were injected into the subcutaneous part of their left foot. The mice were divided into five groups: healthy control group, healthy treatment, tumour control, treatment 1 and treatment 2. Then, 1 mg/kg and 20 mg/kg doses of rosuvastatin were given intraperitoneally. Serum and tissue arginase enzyme activities and tissue ornithine levels were determined spectrophotometrically. HPLC measurement of polyamines were applied. Results: Increased serum arginase activity and polyamine levels were significantly decreased with rosuv- astatin treatment. In the tumour tissue, arginase activity and ornithine levels were significantly decreased in treatment groups compared to the tumour group. Tissue polyamine levels also decreased with rosuvastatin treatment. Conclusion: We suggest that rosuvastatin may have some protective effects on breast cancer development as it inhibits arginase enzyme activity and ornithine levels, precursors of polyamines, and also polyamine levels. This protective effect may be through the induction of nitric oxide (NO) production via nitric oxide synthase (NOS). As a promising anticancer agent, the net effects of rosuvastatin in this mechanism should be supported with more advanced studies and new parameters.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Jenkinson CP, Grody WW, Caderbaum SD. Comparative pro- perities of arginases. Comp Biochem Physiol B Biochem Mol Biol 1996;114:107-32. [CrossRef]
2. Cederbaum SD, Yu H, Grody WW, Kern RM, Yoo P, Iyer RK. Arginases I and II: do their functions overlap? Mol Genet Metab 2004;81:S38-44. [CrossRef]
3. Porembska Z, Luboinski G, Chrzanowska A, Mielczarek M, Magnuska J, Baranczyk-Kuzma A. Arginase in patients with breast cancer. Clin Chim Acta 2003;328:105-11. [CrossRef]
4. Lowe DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 2000;4:441-58. [CrossRef]
5. Bonavida B, Khineche S, Huerta-Yepez S, Garban H. Thera- peutic potential of nitric oxide in cancer. Drug Resist Updat 2006;9:157-73. [CrossRef]
6. Singh R, Avliyakulov NK, Braga M, Haykinson MJ, Martinez L, Singh V, et al. Proteomic identification of mitochondrial targets of arginase in human breast cancer. PLoS One 2013;8:115. [CrossRef]
7. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001;58:244-58. [CrossRef]
8. Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. Biochem J 2003;376:1-14. [CrossRef]
9. Park MH, Igarashi K. Polyamines and their metabolites as di- agnostic markers of human diseases. Biomol Ther (Seoul) 2013;21:1-9. [CrossRef]
10. Luvai A, Mbagaya W, Hall AS, Barth JH. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol 2012;6:17-33.
11. Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. J Cardiovasc Pharmacol 2007;49:376-83. [CrossRef]
12. Schupp N, Schmid U, Heidland A, Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis 2008;199:278-87. [CrossRef]
13. Kotamraju S, Williams CL, Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-depen- dent pathways. Cancer Res 2007;67:7386-94. [CrossRef]
14. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. Th1/Th2- regulated expression of arginase iso- forms in murine macrophages and dendritic cells. J Immunol 1999;163:3771-7.
15. Erbas H, Aydogdu N, Usta U, Erten O. Protective role of carni- tine in breast cancer via decreasing arginase activity and increas- ing nitric oxide. Cell Biol Int 2007;31:1414-9. [CrossRef]
16. Fu S, Xiao C, Zhao W, Yu X. Polyamines analysis by HPLC and their application as tumor markers. Frontiers Biosci (Elite Ed.) 2012;4:1795-801.
17. Ishii N, Ikenaga H, Carmines PK, Aoki Y, Ogawa Z, Saruta T, et al. High glucose augments arginase activity and nitric oxide produc- tion in the renal cortex. Metabolism 2004;53:868-74. [CrossRef]
18. Jansen A, Lewin S, Cattell V, Cook HT. Arginase is a major pathway of L-arginine metabolism in nephritic glomeruli. Kid- ney Int 1992;42:1107-12. [CrossRef]
19. Durak I, Oztürk HS, Elgün S, Cimen MY, Yalçin S. Erythrocyte nitric oxide metabolism in patients with chronic renal failure. Clin Nephrol 2001;55:460-4.
20. Grody WW, Dizikes GJ, Cederbaum SD. Human arginase iso- zymes. Isozymes Curr Top Biol Med Res 1987;13:181-214.
21. Griffith OW, Stuehr DJ. Nitric oxide synthases. Properties and cata- lytic mechanism. Ann Rev Physiol 1995;57:707-36. [CrossRef]
22. Singh R, Pervin S, Karimi A, Cederbaum S, Chaudhuri G. Ar- ginase activity in human breast cancer cell lines. N(omega)- hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells. Cancer Res 2000;60:3305-12.
23. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995;92:4392-6. [CrossRef]
24. Edwards P, Cendan JC, Topping DB, Moldawer LL, MacKay S, Copeland EM, et al. Tumour cell nitric oxide inhibits cell growth in vitro, but stimulates tumorigenesis and experimental lung me- tastasis in vivo. J Surg Res 1996;63:49-52. [CrossRef]
25. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G. Ni- tric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 1994;91:9407-11. [CrossRef]
26. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Nitric oxide in can- cer and chemoprevention. Free Radic Biol Med 2003;34:955-68. http://dx.doi.org/10.1016/S0891-5849(02)01363-1. [CrossRef]
27. Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine mac- rophages induce apoptosis in tumour cells through nitric oxide-de- pendent or -independent mechanisms. Cancer Res 1994;54:2462-7.
28. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-34. [CrossRef]
29. Gotoh T, Araki M, Mori M. Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA. Biochem Biophys Res Commun 1997;233:487-91. [CrossRef]
30. Bachrach U. Polyamines and cancer: minireview article. Amino Acids 2004;26:307-9. [CrossRef]
31. Gugliucci A. Polyamines as clinical laboratory tools. Clin Chim Acta 2004;344:23-35. [CrossRef]
32. Sumi S, Beauchamp RD, Townsend CM, Uchida T, Murakami M, Rajaraman S, et al. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 1992;103:982-9.
33. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92. [CrossRef]
34. Lai SW, Liao KF, Lai HC, Muo CH, Sung FC, Chen PC. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol 2013;28:485-92. [CrossRef]
35. Seiler N. Catabolism of polyamines. Amino Acids 2004;26:217-33. [CrossRef]

APA	ERBAŞ H, BAL O, ÇAKIR E (2015). Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. , 89 - 95.
Chicago	ERBAŞ Hakan,BAL Oğuz,ÇAKIR Erol Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. (2015): 89 - 95.
MLA	ERBAŞ Hakan,BAL Oğuz,ÇAKIR Erol Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. , 2015, ss.89 - 95.
AMA	ERBAŞ H,BAL O,ÇAKIR E Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. . 2015; 89 - 95.
Vancouver	ERBAŞ H,BAL O,ÇAKIR E Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. . 2015; 89 - 95.
IEEE	ERBAŞ H,BAL O,ÇAKIR E "Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer." , ss.89 - 95, 2015.
ISNAD	ERBAŞ, Hakan vd. "Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer". (2015), 89-95.

APA	ERBAŞ H, BAL O, ÇAKIR E (2015). Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. Balkan Medical Journal, 32(1), 89 - 95.
Chicago	ERBAŞ Hakan,BAL Oğuz,ÇAKIR Erol Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. Balkan Medical Journal 32, no.1 (2015): 89 - 95.
MLA	ERBAŞ Hakan,BAL Oğuz,ÇAKIR Erol Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. Balkan Medical Journal, vol.32, no.1, 2015, ss.89 - 95.
AMA	ERBAŞ H,BAL O,ÇAKIR E Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. Balkan Medical Journal. 2015; 32(1): 89 - 95.
Vancouver	ERBAŞ H,BAL O,ÇAKIR E Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer. Balkan Medical Journal. 2015; 32(1): 89 - 95.
IEEE	ERBAŞ H,BAL O,ÇAKIR E "Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer." Balkan Medical Journal, 32, ss.89 - 95, 2015.
ISNAD	ERBAŞ, Hakan vd. "Effect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancer". Balkan Medical Journal 32/1 (2015), 89-95.